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Kidney disease associated with diabetes mellitus is a major health problem worldwide.
Although established therapeutic strategies, such as appropriate blood glucose control,
blood pressure control with renin–angiotensin system blockade, and lipid lowering with
statins, are used to treat diabetes, the contribution of diabetic end-stage kidney disease to
the total number of cases requiring hemodialysis has increased tremendously in the past
two decades. Once renal function starts declining, it can result in a higher frequency of renal
and extra-renal events, including cardiovascular events. Therefore, slowing renal function
decline is one of the main areas of focus in diabetic nephropathy research, and novel
strategies are urgently needed to prevent diabetic kidney disease progression. Regardless
of the type of injury and etiology, kidney ﬁbrosis is the commonly the ﬁnal outcome of
progressive kidney diseases, and it results in signiﬁcant destruction of normal kidney
structure and accompanying functional deterioration. Kidney ﬁbrosis is caused by prolonged
injury and dysregulation of the normal wound-healing process in association with excess
extracellular matrix deposition. Kidney ﬁbroblasts play an important role in the ﬁbrotic
process, but the origin of the ﬁbroblasts remains elusive. In addition to the activation
of residential ﬁbroblasts, other important sources of ﬁbroblasts have been proposed, such
as pericytes, ﬁbrocytes, and ﬁbroblasts originating from epithelial-to-mesenchymal and
endothelial-to-mesenchymal transition. Inﬂammatory cells and cytokines play a vital role
In the process of ﬁbroblast activation. In this review, we will analyze the contribution
of inﬂammation to the process of tissue ﬁbrosis, the type of ﬁbroblast activation and
the therapeutic strategies targeting the inﬂammatory pathways in an effort to slow the
progression of diabetic kidney disease.
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INTRODUCTION
Diabetic nephropathy is the most common cause of end-stage
renal disease (ESRD) worldwide (Ritz et al., 1999; Viswanathan,
1999; Parving, 2001; Remuzzi et al., 2002). Current treatment
strategies may slow but in most of cases cannot arrest progression
toward ESRD (Lewis et al., 1993; Brenner et al., 2001). Once dia-
betic nephropathy progresses to ESRD, management with dialysis
is expensive and is associated with increased cardiovascular mor-
bidity and mortality compared to non-diabetic ESRD (Parving,
2001; Remuzzi et al., 2002).
Therefore, in an effort to aid in the discovery of novel ther-
apeutic concepts that allow the prevention and retardation of
diabetic nephropathy, innovative insight into the pathophysiol-
ogy of diabetic nephropathy is mandatory (Wolf and Ritz, 2003).
Hemodynamic alterations such as hyperﬁltration and hyperperfu-
sion caused by hyperglycemia are considered major kidney injury
factors, but such alterations are only one aspect of a complex series
of pathophysiological alterations related to the presence of glucose
metabolism defects.
Various theories have been proposed concerning the pathogen-
esis of diabetic nephropathy, including proteinuria, genetics, race,
hypoxia, ischemia, and inﬂammation (Fernández Fernández et al.,
2012). Individually, the theories proposed thus far may not be able
to explain the progression of diabetic nephropathy. Among these
theories, inﬂammation appears to be the critical pathway for the
development and progression of diabetic nephropathy.
The role of inﬂammation in diabetic nephropathy has been
reported previously (Mezzano et al., 2003; Rivero et al., 2009;
Wada and Makino, 2013). In the context of current theories
that are focused on inﬂammation and ﬁbroblast activation, such
as epithelial-to-mesenchymal transition (EMT) and endothelial-
to-mesenchymal transition (EndMT), we discuss the role of
inﬂammation in the progression of diabetic kidney disease, with
an emphasis on therapeutic strategies.
GENERAL OVERVIEW OF THE BIOLOGY OF DIABETIC
NEPHROPATHY
MULTIPLE PROFIBROTIC PATHWAY INVOLVEMENT
Various theories have been proposed regarding the development
andprogressionof diabetic kidneydisease. Thepathological events
that have traditionally been implicated in the development of dia-
betic nephropathy include poor glycemic control, hypertension,
proteinuria, and other such factors. Individual factors such as
genetics, race, obesity, and smoking have been shown to contribute
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to variations in the onset and progression of kidney disease
(Bakris et al., 2003; American Diabetes Association, 2011; Cravedi
et al., 2012).
Diabetic organ damage, including diabetic nephropathy, is fun-
damentally triggered by glucose metabolism defects; normalizing
blood glucose levels is essential for diabetic therapy (The Dia-
betes Control and Complications Trial Research Group, 1993;
Ohkubo et al., 1995; UK Prospective Diabetes Study [UKPDS]
Group, 1998). Indeed, pancreatic transplantation in overt diabetic
nephropathy with sclerotic glomeruli can cure the nephropathy
with signiﬁcant amelioration of renal pathology, but the pro-
cess takes nearly 10 years (Fioretto et al., 1993, 1998; Fioretto
and Mauer, 2011). However, the normalization of blood glucose
levels in diabetic patients is challenging, and such intensive ther-
apies in diabetic patients are associated with increased mortality
risk and are likely associated with frequent severe hypoglycemia
(Ismail-Beigi et al., 2010). Although strict control of blood glu-
cose levels inhibits the progression of urine albuminuria levels, it
does not offer any difference in clinical kidney disease outcome
(Hemmingsen et al., 2011; Coca et al., 2012; Slinin et al., 2012).
Therefore, to prevent diabetic complications, therapeutic strate-
gies are required in addition to those that target blood glucose
normalization.
The degree of urine albumin/protein is associated with the
progression of kidney disease via the activation of tubular
angiotensin-converting enzyme (ACE) inhibitors or inﬂammatory
pathways (Abbate et al., 2006; Cravedi et al., 2012; Erkan, 2012).
Strategies to decrease proteinuria with renin–angiotensin system
(RAS) blockade have been shown to be partially renoprotective
(Lewis et al., 1993; Brenner et al., 2001). However, 30% of dia-
betic nephropathies occur in the absence of signiﬁcant proteinuria
(Fernández Fernández et al., 2012), suggesting that other pathways
have a role in the pathogenesis of the condition, and recent clinical
trials raise questions about the signiﬁcance of strong RAS block-
ade using a combinationof RAS inhibitors in diabetic nephropathy
patients (Mann et al., 2008; Parving et al., 2012).
Systemic/intra-glomerular hypertension can result in the onset
and progression of diabetic kidney disease. ACE inhibitors
and angiotensin receptor blockers (ARBs) have been shown to
slow disease progression by controlling hypertension, in addi-
tion to decreasing proteinuria (Lewis et al., 1993; Brenner et al.,
2001). Non-dihydropyridine calcium channel blockers, aldos-
terone antagonists, and direct rennin inhibitors (e.g., aliskiren)
have been reported to control hypertension and reduce albumin-
uria/proteinuria, but evidence of long-term, signiﬁcant clinical
renal outcomes remains lacking (Slinin et al., 2012).
Diabetic insults to the kidney are mediated through the various
pathogenic pathways described above. Inﬂammation appears to be
the ﬁnal common pathway and can result in either kidney repair
if regulated or ﬁbrosis if the process is uncontrolled.
INFLAMMATION AND KIDNEY FIBROSIS
Fibrosis is a sequence of normal wound healing and repair that
is activated in response to injury to maintain the original tis-
sue architecture and ensure normal functional integrity (Pinzani,
2008;Wynn, 2008). Essentially, inﬂammation is required for tissue
repair, except in embryos, where tissue can be repaired without
typical inﬂammation (Bullard et al., 2003; Redd et al., 2004).
Inﬂammation is closely associated with tissue repair, regeneration
of parenchymal cells, and ﬁlling of tissue defects with ﬁbrous tis-
sue, i.e., scar formation (Wynn, 2007). The inﬂammatory response
to an injury eventually results in either (a) the normal tissue
repair process and the regaining of structural and functional
integrity or (b) abnormal and uncontrolled tissue repair, which
leads to progressive ﬁbrosis with loss of tissue structure and func-
tion. Although non-resolving inﬂammation has been shown to
be a major driving force in the development of ﬁbrotic disease,
as described above, inﬂammation is an essential aspect of host
defense mechanisms in response to injury (Wynn, 2007). In this
regard, progressive ﬁbrosis with sustained inﬂammation can be
considered as a type of chronic wound with defects in the normal
healing process (Liu, 2011). Thus, controlling excessive inﬂam-
mation has great therapeutic potential of inhibiting progressive
kidney ﬁbrosis.
Once tissue is injured, inﬂammatory cells inﬁltrate the site of
injury due to the enrichment of pro-inﬂammatory niches at the
site of injury and directional guidance mediated by chemotac-
tic cytokine concentration gradients (Chung and Lan, 2011). The
inﬁltration of inﬂammatory cells, such as lymphocytes, mono-
cytes/macrophages, dendritic cells (DCs) and mast cells, precedes
the process of tissue ﬁbrosis (Chung and Lan, 2011). At the injury
site, activated inﬁltrated inﬂammatory cells can synthesize tissue
damage factors such as reactive oxygen species (ROS) and produce
ﬁbrogenic cytokines and several growth factors (Ricardo et al.,
2008; Dufﬁeld, 2010; Vernon et al., 2010). Sustained inﬂamma-
tory cell activation results in proﬁbrotic cytokine pressure within
the local microenvironment. The cytokine pressure subsequently
primes the ﬁbroblasts at the site of injury and induces tubu-
lar epithelial cell phenotypic changes into a mesenchymal-like
phenotype that produces a large amount of proﬁbrotic extracellu-
lar matrix (ECM) components (Liu, 2011). Therefore, sustained
inﬂammation after the tissue injury could be the initiator, the
trigger and the activator of tissue ﬁbrosis progression.
The importance of inﬂammation in the development and pro-
gression of renal ﬁbrosis has been well documented (Table 1;
Ricardo et al., 2008; Dufﬁeld, 2010; Vernon et al., 2010). Inﬂam-
mation is regulated by the complex interaction of various factors,
involving cytokines, chemokines, and adhesion molecules. Renal
inﬂammation is characterized by glomerular and tubulointer-
stitial inﬁltration by inﬂammatory cells, including neutrophils,
macrophages, lymphocytes, and other such cells, regardless of the
initial injury. Such cellular inﬁltrates are evident in both experi-
mental models of renal disease and human renal biopsy specimens
(Ferenbach et al., 2007). Inﬂammation is initiatedwith the entry of
neutrophils, which take up cell debris and phagocytose apoptotic
bodies (Lee and Kalluri, 2010). Activated neutrophils degranu-
late to release inﬂammatory and proﬁbrotic cytokines (Lee and
Kalluri, 2010). Subsequently, macrophages inﬁltrate damaged tis-
sues and play an important role in the production of inﬂammatory
cytokines and proﬁbrotic cytokines (Lee and Kalluri, 2010). The
recruitment and activation of T lymphocytes has been shown to
be a signiﬁcant early event in the initiation of renal ﬁbrosis, and it
typically precedes the inﬂux of macrophages into the injured kid-
neys (Lin et al., 2008). The importance of T or B lymphocytes has
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Table 1 | Inflammatory cell types and their roles in kidney fibrosis.
Inflammatory
cell type
Major roles in the kidney fibrosis process Reference
Neutrophil Initiation of inﬂammation
Uptake of cell debris
Phagocytosis of apoptotic bodies
Lee and Kalluri (2010)
Lymphocyte T cell recruitment and activation as an early event in the ﬁbrosis process
T cell deﬁciency associated with reduced ﬁbrosis
Cytokine production
Lin et al. (2008), Tapmeier et al. (2010)
Macrophage M1 macrophages exhibit a pro-inﬂammatory phenotype, and M2 macrophages do not
have a typical inﬂammatory phenotype
Generation of various cytokines, chemokines and reactive oxygen species
Ricardo et al. (2008), Lin et al. (2009),
Dufﬁeld (2010), Wang and Harris (2011)
Dendritic cell Capture and deliver antigens to T cells
Stage-speciﬁc role in kidney ﬁbrosis
Heymann et al. (2009), Macconi et al. (2009),
Hochheiser et al. (2011a)
Mast cell Controversial role in ﬁbrosis
Mast cell-deﬁcient mice display increased morality and kidney ﬁbrosis in experimental
animal models
Miyazawa et al. (2004), Kanamaru et al. (2006),
Timoshanko et al. (2006),
Holdsworth and Summers (2008)
been analyzed in genetic mouse models that lack mature B and T
lymphocytes and have a V(D)J recombination-activating protein
1 (RAG1) deﬁciency. RAG1-deﬁcient mice are protected against
ﬁbrosis after obstructive injury (Tapmeier et al., 2010).
Similar anti-ﬁbrogenic effects were observed when CD4+ T
cells were depleted in wild-type mice after obstructive injury (Tap-
meier et al., 2010), whereas reconstitution with puriﬁed CD4+ T
cells in RAG1-knockout (B, T cell-deﬁcient) mice led to restored
ﬁbrogenic responses following obstructive injury (Tapmeier et al.,
2010), suggesting that lymphocytes, especially CD4+ T cells, have
a critical role in the pathogenesis of renal ﬁbrosis induced by
obstructive injury. An analysis of type IV collagen α3 chain-
deﬁcient mice, the model of human Alport syndrome, revealed
that RAG1 deﬁciency in mice signiﬁcantly ameliorated tubuloin-
terstitial injury without amelioration in glomerular basement
membrane (GBM) structures (LeBleu et al., 2008), but strepto-
zotocin (STZ)-induced diabetic animal models using the same
RAG1-deﬁcient mice displayed no alteration in tubular injury
when compared to control diabetic mice, even though RAG1-
deﬁcient diabetic mice exhibited low levels of albuminuria (Lim
et al., 2010). Macrophage inﬁltration into the kidney cortex was
the same in the STZ-induced diabetic RAG1-deﬁcient and con-
trol diabetic mice, suggesting that the major mechanism for the
inﬂammatory sequence was not affected by the absence of lym-
phocytes in their model (Lim et al., 2010); however, these results
must be conﬁrmed in additional studies, such as those using much
stronger diabetic kidney ﬁbrosis models (Sugimoto et al., 2007),
to determine whether this observation is generalizable in diabetic
nephropathy. It is not clear how or whether the various inﬂamma-
tory response processes can affect disease-speciﬁc responses and
subsequent tubule-interstitial injury from ﬁbrosis.
Evidence from renal biopsies has shown that macrophage accu-
mulation in diabetic kidneys predicts declining renal function
(Dufﬁeld, 2010; Wang and Harris, 2011). STZ-induced diabetic
animal models indicate that macrophage accumulation is asso-
ciated with kidney ﬁbrosis (Chow et al., 2004; Sugimoto et al.,
2012). It is believed that macrophages play crucial roles in renal
ﬁbrogenesis (Dufﬁeld, 2010; Wang and Harris, 2011). Mono-
cytes are recruited from circulating blood into the injured sites
in response to tissue damage through cytokine-directed navi-
gation, and subsequently recruited monocytes are differentiated
into two broad but distinct subsets of macrophages: activated
(M1) macrophages and alternatively activated (M2) macrophages
(Ricardo et al., 2008; Lin et al., 2009). It is believed that M1
macrophages exhibit a typical pro-inﬂammatory phenotype via
the generation of various chemokines, as well as ROS. M1
macrophages display pathogenic functions that lead to further tis-
sue injury and ﬁbrosis. In diabetic animal models, the depletion
of the chemokines intercellular adhesion molecule-1 (ICAM-1)
and monocyte chemoattractant protein-1 (MCP-1) diminishes
macrophage accumulation and subsequent inﬂammation and tis-
sue damage (Chow et al., 2005, 2007b). Immunohistological anal-
ysis has revealed that macrophages accumulated in diabetic kidney
injury sites exhibit inducible nitric oxide release,CD169, andphos-
phorylated p38 mitogen-activated protein kinases (Adhikary et al.,
2004; Chow et al., 2007a,b). Macrophage scavenger receptor-A-
deﬁcient mice are protected from interstitial ﬁbrosis in diabetic
nephropathy associated with the amelioration of microinﬂam-
mation (Usui et al., 2007). The depletion of macrophages has
been shown to protect and restore renal ﬁbrosis after vari-
ous injuries in non-diabetic animal models. The reconstitution
of macrophages can worsen existing ﬁbrotic lesions, thereby
demonstrating that they have a proﬁbrotic role in renal ﬁbroge-
nesis (Henderson et al., 2008; Ko et al., 2008a; Lin et al., 2009).
Macrophage activation status is also a major determinant of
their pro-ﬁbrogenic ability. The infusion of toll-like receptor 9
(TLR9) agonist-activated macrophages exaggerated disease pro-
gression in doxorubicin-induced nephropathy in mice, whereas
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resting macrophages did not induce disease progression (Wang
et al., 2008).
Dendritic cells originate from the same bone marrow myeloid
progenitor cells as macrophages, and they abundantly accumulate
in normal kidney interstitium (John and Nelson, 2007; Kaissling
and Le Hir, 2008; Teteris et al., 2011). DCs have important roles in
the regulation of immune tolerance and the mounting of robust
immune responses to pathogens. Macconi et al. (2009) reported
that DCs can produce antigenic peptides from albumin through a
proteasome-dependent pathway in a remnant kidney model. Sub-
sequently, such peptides activate CD8+ T cells, suggesting that
in proteinuric diseases, renal DCs capture and carry ﬁltered anti-
gens to T cells, leading to the production of pro-inﬂammatory
cytokines. The crucial roles of DCs in renal disease progres-
sion and ﬁbrogenesis have been demonstrated in DC-depleted
mice, which exhibit renal protection via the overexpression of the
model antigens, ovalbumin and hen egg lysozyme, in glomerular
oocytes and nephrotoxic serum nephritis models (Heymann et al.,
2009; Hochheiser et al., 2011a). Interestingly, later nephrotoxic
nephritis (NTN) models revealed that DC depletion in late-stage
nephritis halted disease progression but that early-stage deple-
tion augmented disease progression, suggesting that DCs have a
disease phase-speciﬁc role in certain disease models (Hochheiser
et al., 2011a,b). The signiﬁcance of DCs in diabetic kidney ﬁbrosis
remains unclear (Tu et al., 2010).
The role of mast cells in renal ﬁbrogenesis remains contro-
versial and unclear (Kanamaru et al., 2006; Timoshanko et al.,
2006; Holdsworth and Summers, 2008). In diabetic kidney dis-
ease, mast cell numbers have been correlated with interstitial
ﬁbrosis (Hiromura et al., 1998; Sakamoto-Ihara et al., 2007). How-
ever, analyses of mast cell-deﬁcient experimental animal models
have suggested that mast cells have renal-protective roles. Indeed,
in experiments, mast cell-deﬁcient mice exhibited increased
mortality and histopathological deteriorations in anti-GBM syn-
drome disease models (Kanamaru et al., 2006). Interstitial ﬁbrosis
was augmented in mast cell-deﬁcient mice compared to con-
trol animals, which was demonstrated using a puromycin amino
nucleoside-nephritis model (Miyazawa et al., 2004).
The evidence described above clearly demonstrates that the
activation of inﬂammatory lymphocytes, macrophages, and DCs
is essential for ﬁbrotic kidney disease initiation and progression,
including diabetic kidney disease.
INFLAMMATION: FIBROBLAST ACTIVATION
The local accumulation of proﬁbrotic cytokines in the microen-
vironment following kidney injury leads to the activation of
ECM-producing cells, which are essential for renal ﬁbrogenesis.
As discussed above, almost all cell types in the tubulointerstitium
of the kidneys, such as residential ﬁbroblasts, tubular epithelial
cells, vascular smooth muscle cells, and a subset of macrophages,
are responsible for producing ECM. The fundamental matrix-
producing cells that generate a large amount of interstitial matrix
components, including ﬁbronectin and type I and type III col-
lagens, are ﬁbroblasts (Strutz and Zeisberg, 2006). Proﬁbrotic
cytokine transforming growth factor-beta (TGF-βs) has been
shown to play an essential role in this process, and the inhi-
bition of TGF-βs or the TGF-β-stimulated smad transcriptional
factor signaling pathway blockade has been shown to exhibit anti-
ﬁbrotic effects (Border andNoble,1994;Miyazono,2000; Kanasaki
et al., 2003, 2011; RamachandraRao et al., 2009; Takakuta et al.,
2010; Hills and Squires, 2011; Lan, 2011; Sharma et al., 2011; Choi
et al., 2012).
TGF-βs modulate the overall response by affecting different
receptors and downstream signaling. Active TGF-βs have proﬁ-
brotic effects, and latent TGF-βs have an anti-ﬁbrotic effect (Lan,
2011; Meng et al., 2013). The smad pathway is a downstream sig-
naling pathway that can be inﬂuenced by non-TGF-βs molecules,
such as angiotensinogen and advanced glycation end products.
Among the smad molecules, smad 2 and smad 7 are likely reno-
protective, and smad 3 is pathogenic (Meng et al., 2010, 2013; Lan,
2011; Lan and Chung, 2012).
In diseased kidneys, activated ﬁbroblasts express α smooth
muscle actin (αSMA) and are often referred to as myoﬁbroblasts.
These types of cells possess unique contractile properties (Strutz
and Zeisberg, 2006). In the renal ﬁbrosis process, renal myoﬁ-
broblasts are believed to be an activated ﬁbroblast phenotype
that essentially contributes to ECM production and deposi-
tion in tubulointerstitial ﬁbrosis (Strutz and Zeisberg, 2006).
Several studies have examined the origin, activation, and reg-
ulation of these matrix-producing myoﬁbroblasts (Grande and
Lopez-Novoa, 2009; Meran and Steadman, 2011).
Figure 1 brieﬂy summarizes the ﬁve well-reported sources of
matrix-producing myoﬁbroblasts, including the activation of res-
idential ﬁbroblasts, differentiation of pericytes, recruitment of
circulatingﬁbrocytes, and conversionof tubular epithelial cells and
endothelial cells intomesenchymal cells (Barnes andGorin, 2011).
The relative contribution to and even the existence of each par-
ticular myoﬁbroblast-generating pathway in renal ﬁbrosis is still a
topic of intense debate (Zeisberg and Dufﬁeld, 2010). Difﬁculty
with identifying and tracking the lineage of ﬁbroblasts, matrix-
producing myoﬁbroblasts, and other cell types due to the lack of
speciﬁc markers has made the theory very controversial. Despite
this controversy, there is no doubt that such matrix-producing
ﬁbroblasts exhibit signiﬁcant heterogeneity.
INFLAMMATION: ACTIVATION OF RESIDENTIAL FIBROBLAST AND
PERICYTES
Historically, all matrix-producing myoﬁbroblasts were thought to
originate from residential ﬁbroblasts by phenotypic activation fol-
lowing renal injury and inﬂammation (Hewitson, 2009; Figure 2).
This concept has recently been debated and challenged (Strutz
and Zeisberg, 2006; Grande and Lopez-Novoa, 2009; Zeisberg and
Dufﬁeld, 2010).
Fibroblasts are localized in the interstitial space between the
capillaries and the epithelia in normal kidneys. They are organized
as a network spread throughout the renal parenchyma, where they
stabilize and organize the tissue architecture (Kaissling and Le Hir,
2008). Morphological analysis has revealed that these ﬁbroblasts
are stellate shaped and display a rough endoplasmic reticulum,
collagen-containing granules and actin ﬁlaments (Strutz and Zeis-
berg, 2006). They exhibit multiple cell processes, which enable
them to interact with the tubular and capillary basement mem-
branes (Kaissling and Le Hir, 2008). In quiescent states, interstitial
ﬁbroblasts express CD73 (also known as ecto-5′-nucleotidase)
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FIGURE 1 | Diverse origins of fibroblasts. Kidney ﬁbrosis is a well-
coordinated event originating from various sources (1, interstitial cells; 2,
pericytes; 3, ﬁbrocytes; 4, tubular epithelial cells; 5, endothelial cells) and
processes (recruitment, activation, differentiation, epithelial-to-mesenchymal
transition, and endothelial-to-mesenchymal transition) that contribute to
myoﬁbroblast activation/formation.
in their plasma membrane and are responsible for producing
erythropoietin (Kaissling and Le Hir, 2008; Paliege et al., 2010).
These cells also express platelet-derived growth factor receptor
β (PDGFRβ; Floege et al., 2008) and ﬁbroblast-speciﬁc protein
1 (FSP1; also known as S100A4), a small protein that exhibits
a calcium-binding motif and is associated with the cytoskele-
ton (Wynn, 2007). Under normal conditions, ﬁbroblasts are
responsible for maintaining the homeostasis of the interstitial
matrix against physiologic conditions by producing an essential,
basal level of ECM components. Following proﬁbrotic cytokine
inﬂammation and mechanical stress, these interstitial ﬁbroblasts
undergo phenotypic change into myoﬁbroblasts by expressing
αSMA, and they begin to produce a large amount of ECM com-
ponents. Myoﬁbroblasts can express both FSP1 and PDGFRβ.
In addition, myoﬁbroblasts can also express de novo vimentin
(an intermediate ﬁlament protein). The myoﬁbroblast phenotype
is indeed a mixture of both matrix component-producing acti-
vated ﬁbroblasts and αSMA-expressing highly contractile smooth
muscle cells.
Fibroblasts become activated by stimulation with cytokines,
including TGF-βs, connective tissue growth factor (CTGF),
platelet-derived growth factor (PDGF), and ﬁbroblast growth
factor 2 (FGF2; Liu, 2011). In addition to cytokine-mediating
reactions, direct cell–cell interactions (with leukocytes and
macrophages), ECM–integrin interactions, hypoxia, and hyper-
glycemia could contribute to the activation process (Chow et al.,
2004, 2007a; Liu, 2011). In tubulointerstitial ﬁbrosis, renal ﬁbrob-
lasts maintain an activated status, even after the initial injury
and insult has ceased (Liu, 2011). Activated ﬁbroblasts are char-
acterized by two key features: proliferation and myoﬁbroblastic
activation (Strutz and Zeisberg, 2006). However, the proliferation
of residential ﬁbroblasts is also controversial, and some reports
have indicated that no proliferation occurs in unilateral ureteral
obstruction renal ﬁbrosis models (Yamashita et al., 2005). Myoﬁ-
broblastic activation is illustrated by αSMA expression and matrix
production (Strutz and Zeisberg, 2006). Both ﬁbroblasts and
myoﬁbroblasts have the ability to proliferate when stimulated with
cytokines. This ﬁbroblast proliferation results in the expansion of
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FIGURE 2 | Activation of fibroblasts. Internal milieu changes (hypoxia, high glucose, integrin interactions, and production of reactive oxygen species) and
proﬁbrotic inﬂammatory cytokines from varied cell sources (macrophages, lymphocytes, and damaged tubular epithelial cells) result in ﬁbroblast activation,
which initiates and sustains the process of ﬁbrosis.
the ﬁbroblast population and ECM deposition in the interstitial
space in damaged kidneys (Strutz and Zeisberg, 2006). Fibroblasts
are activated and proliferate in response to several cytokines and
mitogens, such as PDGF, TGF-β, basic FGF2, and CTGF. These
cytokines are also potentially derived from activated macrophages
(Strutz et al., 2000; Bottinger, 2007; Hewitson, 2009; Phanish et al.,
2010; Boor and Floege, 2011; Ostendorf et al., 2012).
Tissue-type plasminogen activator (tPA), which can also be
derived from activated macrophages, is another critical factor in
kidney ﬁbrosis (Hu et al., 2007, 2008; Hao et al., 2010; Lin et al.,
2010). tPA plays crucial roles in the pathogenesis of renal intersti-
tial ﬁbrosis through a variety of mechanisms, such as protection
from apoptosis and induced mitogenesis (Hu et al., 2007, 2008;
Hao et al.,2010; Lin et al.,2010). In renal interstitial ﬁbroblasts, tPA
also induces the expression of matrix metalloproteinase-9 (MMP-
9), which causes destruction of the tubular basement membrane
(TBM), subsequently leading to tubular EMT (Hu et al., 2006). tPA
also acts independently of its protease activity and induces myoﬁ-
broblast activation of quiescent interstitial ﬁbroblasts through
low density lipoprotein (LDL) receptor-related protein 1 (LRP-
1)-mediated recruitment of β1 integrin signaling in rat kidney
ﬁbroblasts (Hu et al., 2006, 2007). Two downstream effectors
of integrin signaling, focal adhesion kinase and integrin-linked
kinase (ILK), control ﬁbroblast proliferation and matrix produc-
tion, respectively (Hao et al., 2010). tPA also acts as a survival
factor that protects renal interstitial ﬁbroblasts/myoﬁbroblasts
from apoptosis, resulting in the expansion of the myoﬁbroblast
population in diseased kidneys.
Some studies have suggested that vascular pericytes are a major
source of myoﬁbroblasts in ﬁbrotic kidneys (Lin et al., 2008;
Humphreys et al., 2010; Schrimpf and Dufﬁeld, 2011). However,
this concept remains controversial (Zeisberg and Dufﬁeld, 2010),
largely due to difﬁculties in deﬁning what constitutes a pericyte.
Pericytes are one subset of the stromal cells, whichoffer endothelial
partial support by covering capillary walls to aid in stabilization.
The markers for pericytes used in several reports that indicate
pericyte–myoﬁbroblast conversions, such as PDGFRβ, are not
absolutely speciﬁc and are indeed expressed in many cell types,
including ﬁbroblasts. Fibroblasts are intricately connected to the
capillaries via cell processes in the renal interstitium (Liu, 2011).
Some reports have suggested that once kidneys are damaged, per-
icytes no longer adhere to the endothelium and that thereafter,
these cells migrate, proliferate, and ﬁnally differentiate into myoﬁ-
broblasts (Figure 2; Lin et al., 2008; Humphreys et al., 2010). In
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addition, the blockade of PDGFR signaling by imatinib reduces
the number of myoﬁbroblasts and restores renal damage in UUO
models (Chen et al., 2011). These results also do not entirely sup-
port pericyte conversion into myoﬁbroblasts but do indicate that
PDGF signaling is a crucial player in kidney ﬁbrogenesis (LeBleu
and Kalluri, 2011). Although the pericyte conversion concept is
interesting, it requires further study to verify whether pericytes
and interstitial ﬁbroblasts are, in fact, the same entity (Kaissling
and Le Hir, 2008).
INFLAMMATION: BONE MARROW-DERIVED CELL RECRUITMENT
Fibrocytes, which are a subset of bone marrow-derived circulating
monocytes, also display ﬁbroblast-like features in the peripheral
blood and are another possible source of ﬁbroblasts (Herzog and
Bucala, 2010). Human ﬁbrocyte precursors can be co-puriﬁed
together with CD14+ monocytes (Peng et al., 2011). In mice, the
ﬁbrocyte transition from monocytes is enhanced with the expres-
sion of CD11b, CD115, and Gr1 (Niedermeier et al., 2009). The
transition is stimulated by direct contact with activated CD4+
lymphocytes and ismediated via amammalian target of rapamycin
(mTOR)–PI3-dependent pathway (Niedermeier et al., 2009). Dif-
ferentiated ﬁbrocytes are negatively regulated by the Fcγ receptors
CD64 and CD32, as indicated by the inhibition of such recep-
tors with serum amyloid P, which inhibits ﬁbrocyte accumulation
in human and experimental animal models (Pilling et al., 2003,
2006, 2007) through immunoreceptor tyrosine-based inhibitory
motif-dependent mechanisms (Pilling et al., 2006). Fibrocyte dif-
ferentiation is stimulated by the Th2 cytokines interleukin (IL)-4
and IL-13 and TGF-β1, which is aided by integrin β1 and inhib-
ited by Th1 cytokines such as interferon-gamma (IFN-γ), tumor
necrosis factors (TNF), and IL-12. TLR2 agonists indirectly inhibit
ﬁbrocyte differentiation, and it is likely that this inhibition involves
the mechanisms by which other cell types in the peripheral blood
mononuclear cell population secrete unknown ﬁbrocyte differ-
entiation inhibitory factors (Maharjan et al., 2010). As TLR2 is
a receptor for immunopathogens, it is possible that some bacte-
rial signals can inhibit ﬁbrocyte differentiation and may thus slow
wound closure (Maharjan et al., 2010).
Fibrocytes display the characteristics of both ﬁbroblasts and
hematopoietic cells, as they are spindle-shaped and express the
hematopoietic cell marker CD45. Fibrocytes have the ability to
produce type I collagen (Pilling et al., 2009; Wada et al., 2011).
Interestingly, ﬁbrocytes also display certain chemokine recep-
tors, such as CCR1, CCR2, CCR7, CXCR4 in mice (Sakai et al.,
2006; Mehrad et al., 2009; Ekert et al., 2011; Scholten et al., 2011)
and CCr2, CCR3, CCr5, and CXCR4, as well as the β1 inte-
grin subunit, and semaphorin 7a in humans (Abe et al., 2001;
Mehrad et al., 2009; Ekert et al., 2011; Gan et al., 2011). Following
kidney injury, ﬁbrocytes have been hypothesized to mobilize, inﬁl-
trate the renal parenchyma and participate in ﬁbrogenesis. The
differentiation of ﬁbrocytes is also regulated through the other
inﬂammatory cells, such as CD4+ T cells, via the production
of cytokines (Niedermeier et al., 2009). The proﬁbrotic inﬂam-
matory cytokines IL-4 and IL-13 induce the differentiation of
ﬁbrocytes, whereas anti-ﬁbrotic cytokines such as IFN-γ and IL-
12 inhibit ﬁbrocyte differentiation, as expected (Shao et al., 2008).
Interestingly, the calcineurin inhibitor cyclosporine promotes
ﬁbrocyte differentiation, suggesting a possible explanation for
cyclosporine-induced nephrotoxicity in clinical settings (Nieder-
meier et al., 2009). The inhibition of angiotensin II type-1 receptor
signaling prevents the accumulation of ﬁbrocytes in the kidneys
aswell as the bonemarrow inmousemodels of renal ﬁbrosis (Sakai
et al., 2008).
Nevertheless, the signiﬁcance of ﬁbrocytes in renal ﬁbrogenesis
remains controversial. Similar to the issues with other theories,
there are no speciﬁc markers for these cells to allow a clear dis-
tinction of ﬁbrocytes from other types of cells, such as monocytes,
macrophages, ﬁbroblasts, and myoﬁbroblasts. Adding to the con-
troversy, it has been shown that there are subpopulations of
ﬁbrocytes (Pilling et al., 2009). The role of ﬁbrocytes, or bone
marrow-derived cells, in renal ﬁbrosis is inconsistent, yet (Iwano
et al., 2002; Roufosse et al., 2006; Lin et al., 2008; Niedermeier et al.,
2009) studies have shown that a considerable ratio of all collagen-
producing ﬁbroblasts in a mouse model of UUO that originate
from ﬁbrocytes or bone marrow-derived cells (Iwano et al., 2002;
Niedermeier et al., 2009); however, other studies using the same
model have reported contradictory results (Roufosse et al., 2006;
Lin et al., 2008, 2009). If there is a speciﬁc ﬁbrocyte lineage, it must
contribute to the tissue repair process. The role of bone marrow
cells in tissue repair has been reported in studies of genetic defects
in type IV collagen α3 chain knockout mice, the model of human
Alport syndrome (Sugimoto et al., 2006). Therefore, some bone
marrow cell lineages must be involved in tissue repair. As ﬁbrosis
is the end result of uncontrolled tissue repair and wound healing
processes, it is reasonable that ﬁbrocytes have a role in ﬁbrogenesis
when they accumulate excessively at the injured site.
INFLAMMATION: EMT AND EndMT
During embryogenesis, the epithelia exhibit high plasticity, and
they can alternate between epithelia and mesenchyme through
the processes of EMT and mesenchymal-to-epithelial transition
(MET; Thiery, 2002; Kalluri and Neilson, 2003). When organ
development is completed, the epithelia typically display special-
ized functions, and this specialization is believed to be a terminal
differentiation (Gumbiner, 1992; Yeaman et al., 1999). However,
recent biological evidence has shed new light on the plasticity
of epithelia, which were formerly considered terminally differ-
entiated cells. Using human renal biopsy samples, the number
of tubular epithelial cells with EMT features has been shown to
be associated with serum creatinine and the degree of damage
(Rastaldi et al., 2002). In addition, EMT has been reported in
canine glomerulonephritis (Aresu et al., 2007). More than 100
studies have demonstrated the potential signiﬁcance of EMT in
kidney ﬁbrosis by examining the phenotypic conversion of tubu-
lar cells in animal models as well as in renal biopsy samples from
various kidney disease patients (Yang and Liu, 2002; Zeisberg et al.,
2003; Hertig et al., 2008; Boonla et al., 2011; Togawa et al., 2011).
Morphological evidence indicates that epithelial cells do indeed
traverse the disrupted TBM into the interstitium after kidney
injury in UUO in mice (Yang et al., 2002). EMT in human dis-
eases, such as inﬂammatory bowel diseases and several cancers,
has been reported (Kalluri and Weinberg, 2009). This evidence
strongly suggests that epithelial plasticity and the occurrence of
EMT play a role in certain human disease conditions.
www.frontiersin.org February 2013 | Volume 4 | Article 7 | 7
“fendo-04-00007” — 2013/2/4 — 21:25 — page 8 — #8
Kanasaki et al. Role of inﬂammation in ﬁbroblast activation
Using a genetic-lineage tracking, Iwano et al. (2002) reported
that over one-third of FSP1+ interstitial ﬁbroblasts originated
from the tubular epithelia in a mouse model of obstructive
nephropathy. Although such evidence strongly suggests the pres-
ence of EMT in tissue ﬁbrosis, some recent experimental studies
using lineage-tracing have reported that the epithelial or endothe-
lial origin of ﬁbroblasts is unclear (Humphreys et al., 2010; Li et al.,
2010). These reports were questioned in a review (Zeisberg and
Dufﬁeld, 2010). EMT-associated matrix-producing mesenchymal
cells deﬁnitely exist, but EMT in ﬁbrogenesis does not necessarily
indicate de novo production of ﬁbroblast from tubular epithelial
cells (Figure 3),which is the extremeoutcomeof EMT(Kalluri and
Weinberg, 2009; Zeisberg and Dufﬁeld, 2010; Figure 3). The num-
ber of epithelial cells undergoing EMT does not necessarily need
to be identical or even similar to the number of cells that become
ﬁbroblasts (Zeisberg and Dufﬁeld, 2010). Fibroblasts proliferate
at the injured site regardless of their origin. Therefore, even if the
original EMT-derivedﬁbroblastswere aminorpopulation tobegin
with, they would proliferate and constitute a large portion of the
ﬁbroblasts, producinghuge amounts of ECMcomponents (Kalluri
and Weinberg, 2009; Zeisberg and Dufﬁeld, 2010). Furthermore,
as described above, EMT is a dynamic and even reversible process,
and thus, intermediate EMT in tubular epithelial cells is more
abundant compared to the extreme ﬁbroblast end points of EMT.
Therefore, the ratio of epithelial cells proceeding to complete EMT
and complete conversion into ﬁbroblasts is reasonably very low
and depends heavily on disease model factors. It is likely that fac-
tors such as longer exposure to the micro-inﬂammatory milieu
and the persistence of raised cytokine pressure are more likely to
induce EMT (Liu, 2004; Kalluri and Weinberg, 2009; Zeisberg and
Dufﬁeld, 2010).
Epithelial-to-mesenchymal transition is an important and use-
ful therapy target in treating kidney disease. The blockade of
EMT with various agents, such as bone morphogenetic protein
(Zeisberg et al., 2003; Sugimoto et al., 2007), hepatocyte growth
factor (Yang and Liu, 2002), ILK inhibitor (Li et al., 2009b), Wnt
antagonists (Surendran et al., 2005; He et al., 2009), and parical-
citol (Tan et al., 2006), as well as the induction of endogenous
heat shock protein (Wynn, 2007; Zhou et al., 2010), has been
shown to ameliorate renal ﬁbrosis and preserve kidney function
in various animal models. Nuclear factor (erythroid-derived 2)-
like 2 (Nrf2), a master regulator of oxidative stress and a potential
drug target for diabetic nephropathy (Pergola et al., 2011; Li et al.,
2012), has an inhibitory effect on the EMT process via interac-
tion with heme oxygenase-1 (Shin et al., 2010). In addition, it
was recently shown that BMP7 receptor Alk3 in renal tubules
is essential for anti-ﬁbrogenesis and tissue repair in the kidneys;
Alk3-agonistic compounds were also shown to exhibit renal pro-
tection in experimental kidney ﬁbrosis models, including models
of diabetic nephropathy; this renal protection was associated with
the inhibition of EMT, inﬂammation, and apoptosis (Sugimoto
et al., 2012).
Fibroblasts and/ormyoﬁbroblasts can be derived from capillary
endothelium through the EndMT (Zeisberg et al., 2008; Li et al.,
2009a). EndMT is considered to be a unique form of EMT, as
endothelial cells are a specialized type of epithelia. Zeisberg et al.
(2008) investigated the contribution of EndMT in renal ﬁbro-
sis in three mouse models of chronic kidney disease, including
STZ-induced diabetic nephropathy. When analyzed according to
the presence of endothelial marker CD31 and the (myo)ﬁbroblast
markers αSMA and FSP1 in conjunction with lineage tracing,
approximately 40% of all FSP-1-positive and 50% of αSMA-
positive cells in STZ kidneys were also CD31 positive (Zeisberg
et al., 2008), suggesting a signiﬁcant contribution of EndMT in
kidney ﬁbrosis. Li et al. (2009a) also reported a contribution
of EndMT in diabetic glomerular sclerosis as well as interstitial
ﬁbrosis in early diabetic mice.
Biological analysis has revealed that EndMT is also regulated
by a combination of various inﬂammatory cytokine pressures.
Although the role of inﬂammatory cytokines in EndMT and
kidney ﬁbrosis has not been clearly established, it is likely that
inﬂammation is a critical mediator in EndMT. In an inﬂammatory
FIGURE 3 | Process of epithelial-to-mesenchymal transition. Epithelial-to-mesenchymal transition is a phenomenon that is well-orchestrated by
inﬂammatory cytokines and results in epithelial cells gradually losing their cell markers and acquiring the mesenchymal phenotype.
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bowel diseasemodel, Rieder et al. (2011) clearly demonstrated that
either a combination of TGF-β1, IL-1β, and TNF-α or activated
lamina propria mononuclear cell supernatants induced morpho-
logical and phenotypic changes consistent with EndMT; each
inﬂammatory cytokine alone had limited effects on endothe-
lial phenotypic changes (Rieder et al., 2011). Another recent
report indicated that the inﬂammatory transcriptional factor
nuclear factor-kappaB (NFκB)determined inﬂammation-induced
EndMT (Maleszewska et al., 2012). These reports suggest that
inﬂammation has a crucial role in the pathogenesis of EndMT.
TGF-βs, IL-1β, and TNF-α expression are indeed increased at the
site of kidney injury in diabetes (Lim and Tesch, 2012). It has been
shown that IL-1, IL-6, IL-18, and TNF-α are likely relevant in
diabetic nephropathy.
Fibroblasts heterogeneity has been established, and such het-
erogeneity could be explained in part by various ﬁbroblast origins,
such as residential ﬁbroblast activation, pericyte conversion, ﬁbro-
cyte origination, and EMT/EndMT. In addition, kidney ﬁbroblasts
in diabetic kidneys could be somewhat different from those of
other kidney diseases. Fibroblasts isolated fromdiabetic skin ulcers
exhibited diverse morphological and functional characteristics
when compared to normal skin ﬁbroblasts (Loots et al., 1999; Xu
et al., 2012b). It also likely that ﬁbroblast activation from ﬁbrob-
lasts, pericytes, or ﬁbrocytes is an early event (Kaissling and Le
Hir, 2008), whereas EMT and/or EndMT contribute at a late stage
after longer, sustained injury (Figure 2; Liu, 2004). In each type of
ﬁbroblast activation process and the sequential process of kidney
ﬁbrogenesis, inﬂammatory cells and their produced cytokines play
a crucial role.
VARIATION IN SUSCEPTIBILITY FOR DIABETIC NEPHROPATHY: THE
ROLE OF VARIATION IN INFLAMMATORY RESPONSE
Variations in conventional risk factors, which include variations
in blood sugar control, blood pressure control, and proteinuria
control, can contribute to variations in diabetic nephropathy
susceptibility (Fernández Fernández et al., 2012).
Genetic polymorphisms in a variety of molecules involved in
pathogenic pathways of diabetic nephropathy could contribute
to the variation in individual susceptibility (Brorsson and Pociot,
2011). Genetic polymorphisms can affect important pathogenic
pathways such as the renin–angiotensin pathway, the inﬂamma-
tory cytokine pathway, the nitric oxide pathway, the bradykinin
pathway, the Wnt pathway, Notch signaling, and the matrix
metalloprotease-related pathway, and have an impact on the devel-
opment and progression of diabetic nephropathy (Maeda, 2008;
Brorsson and Pociot, 2011; Kure et al., 2011).
The cytokine milieu is more important than individual
cytokine levels because cytokines exhibit pleiotropism, redun-
dancy, synergism, antagonism, trans-modulation, and trans-
signaling. The effect of the overall cytokine milieu, rather
than individual cytokine levels, inﬂuences this effect (Navarro-
Gonzalez et al., 2011; Elmarakby and Sullivan, 2012). The vari-
ations in the cytokine response that is mediated by genetic
variation can contribute to the variations observed in diabetic
nephropathy.
Variations in TLRs also modulate the response based on the
level of antigenic exposure and their location in particular organs
(Huebener and Schwabe, 2012). Too much immunity results
in autoimmune disorders, and too little immunity results in
infections. Thus, optimal immunity requires a balance between
autoimmunity and opportunistic infections (Thomas, 2010; Fujio
et al., 2012). There are no exact cutoff values that deﬁne high,
optimal, or low immunity levels for inﬂammatory mediators.
Acute and transient elevations in cytokines lead to different activ-
ity than does chronic low-grade elevation. Infection and injury
that produce transient stimulus of the immune or inﬂammatory
systems resolve without resulting in ﬁbrosis (Serhan et al., 2007).
If an infection or injury is chronic (e.g., tuberculosis or non-
healing wounds), ﬁbrosis can result (dos Santos et al., 2012;
Franchi et al., 2012).
Persistent injury or inﬂammation after an unknown period
of time can result in permanent changes in the inﬂammatory
response, resulting in the unregulated production of proﬁbrotic
factors. Even controlling the inciting stimulus at that time may
not be able to prevent the progression of the disease due to
epigenetic alterations (Gaede et al., 2008; Bechtel et al., 2010; Xu
et al., 2012a).
A multifaceted and sequential approach may be needed for
the management of diabetic kidney ﬁbrosis (Gaede et al., 2008).
Diabetic kidney disease pathways are redundant with respect to
the multiple pathogenic factors that can activate the ﬁnal ﬁbrosis
pathway. At different stages of disease, different pathogenic path-
ways predominate, necessitating the initiation of therapies in a
sequential manner.
Glycemic control is beneﬁcial for preventing micro-vascular
complications in newly diagnosed diabetic patients, as reported by
the DCCT and UKPDS trials, but it is not beneﬁcial in established
diabetic patients for the prevention of signiﬁcant outcomes of dia-
betic nephropathy, as reported in recent trials (Hemmingsen et al.,
2011; Coca et al., 2012; Slinin et al., 2012). Late-stage diabetes,
hypertension, and proteinuria may be the predominant causes
of the progression of diabetic nephropathy, necessitating anti-
hypertensive/antiproteinuric measures to prevent further disease
progression.
Multiple and sequential management includes the initial blood
sugar control and blood pressure control, followed by anti-
inﬂammatory, anti-EMT/EndMT, and anti-ﬁbroblast activation
medications at different stages of diabetic kidney disease (Goel
and Perkins, 2012).
PERSPECTIVE: SLOWING THE PROGRESSION OF DIABETIC KIDNEY
DISEASE – THE ROLE OF INFLAMMATORY PATHWAYS
Existing therapies targeting glucose control, blood pressure con-
trol, and proteinuria reduction, alone or in combination, have
failed to slow or reverse the progression of diabetic nephropathy.
As is evident in the above discussion, the role of inﬂamma-
tion in the initiation and progression of diabetic nephropathy is
undisputed.
Basic studies using various animal models have demon-
strated pro-inﬂammatory cytokine gene activation in diabetic
nephropathy (Navarro et al., 2005, 2006; Navarro-Gonzalez et al.,
2009). Various existing drugs, which have anti-inﬂammatory
activity, have been shown to slow or reverse diabetic kidney
disease.
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ANTI-INFLAMMATORY THERAPIES
An aldosterone antagonist (spironolactone) inhibits NFκB,
thereby inhibiting MCP-1 (Han et al., 2006). Pioglitazone, a
peroxisome proliferator-activated receptor (PPAR) agonist, has
been shown to slow diabetic nephropathy by downregulating
various pro-inﬂammatory and proﬁbrotic genes, such as NFkB,
CCL2, TGF-β1, plasminogen activator inhibitor-1 (PAI-1), vascu-
lar endothelial growth factor (VEGF), etc. (Ko et al., 2008b). ACE
inhibitors and ARBs suppress NFκB signaling and thereby sup-
press the inﬂammatory response (Kim et al., 2011). Pentoxifylline,
TNF-α receptor fusion proteins and chimeric monoclonal anti-
bodies have been shown to decrease TNF-α, a pro-inﬂammatory
cytokine, thereby decreasing ﬁbrosis (Navarro-Gonzalez et al.,
2009). Bardoxolone mesylate is a novel triterpenoid agent with
Nrf-2 agonistic activity that has been shown to have anti-
inﬂammatory and anti-oxidant activity. It inhibitsNFκBand Janus
kinase/signal transducers and activators of transcription (JAK-
STAT) signaling and acts as an anti-oxidant and inﬂammatory
modulator (Zhang, 2013). This compound was expected to be a
useful drug for diabetic nephropathy in an early clinical trial (Per-
gola et al., 2011); however, further clinical trials evaluating the
renoprotective effects of this drug against diabetic nephropathy
were terminated due to increased cardiac events in the drug-
treated group (Zhang, 2013). Finally, cyclooxygenase (COX)-2,
a pro-inﬂammatory enzyme responsible for the formation of
inﬂammatory prostanoids, is induced in diabetic kidneys (Komers
et al., 2001), and preclinical data suggest that COX-2 inhibitors
decrease proteinuria and preserve glomerular structure in animal
models of diabetic nephropathy (Cheng et al., 2002; Komers et al.,
2007; Matsunaga et al., 2007; Nasrallah et al., 2009; Quilley et al.,
2011). However, clinical trials have not yet revealed any signiﬁcant
clinical outcomes of COX-2 inhibition on diabetic nephropathy
(Sinsakul et al., 2007; Cherney et al., 2008a,b). In addition, the
enhanced expression of COX-2 is involved in maintaining ade-
quate renal hemodynamics and function in some patients with
diabetic nephropathy (Khan et al., 2001). Therefore, the inhi-
bition of COX-2 would be harmful in a certain set of diabetic
nephropathy patients.
In view of the current understanding of the central role of
inﬂammation in diabetic nephropathy progression, future studies
may focus on maintaining epithelial integrity, halting the process
of EMT/EndMT transition and controlling the cytokine milieu.
Future diabetic nephropathy research could be directed toward
inhibiting the inﬂammatory pathway in conjunction with con-
ventional therapeutic strategies (Navarro and Mora, 2006; Rivero
et al., 2009), although a few fundamental questions remain.
Indeed, in contrast to the experimental animal model studies,
anti-inﬂammatory therapy has been notably ineffective in halt-
ing kidney ﬁbrogenesis in clinical settings. Furthermore, anti-
inﬂammatory therapy has worsened clinical outcomes in patients
with lung ﬁbrosis and systemic sclerosis (Wynn, 2011; Mur-
ray et al., 2012). These reports suggest that anti-inﬂammatory
therapy would not be effective or could even worsen clinical
outcomes in patients with established diabetic nephropathy and
ﬁbrosis. Additionally, there is a possibility that inﬂammation is
an important initiator of ﬁbrosis, as described above, although
in the advanced chronic ﬁbroproliferative stage, inﬂammation
would act in an alternative manner to facilitate organ repair
and protection. Therefore, examining stage-speciﬁc inﬂamma-
tion in diabetic nephropathy and its associated ﬁbrosis, as well
as identifying reliable biomarkers, is required before inﬂamma-
tion can be used as a therapeutic target in the treatment of this
condition.
CONCLUSION
Diabetic nephropathy is a devastating kidney disease that con-
tributes to the majority of end-stage kidney disease cases world-
wide, and this condition is associated with a higher frequency of
cardiovascular events. Diabetic nephropathy is associated with the
activation of a variety of pathways that lead to the progression
of kidney disease. Among these pathways, inﬂammatory pathway
activation plays a central role. The inﬂammatory pathway leads
to the activation and recruitment of the ﬁbroblasts, which in turn
initiate and sustain the ﬁbrotic process. Apart from conventional
glucose control and blood pressure control, targeting the speciﬁc
pathways that lead to the activation of inﬂammation and ﬁbrob-
lasts could be a new and effective intervention in the management
of diabetic nephropathy.
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